{"id":"vvz-149-injections","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, VVZ-149 Injections prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.","oneSentence":"VVZ-149 Injections is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:58.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05764525","phase":"PHASE3","title":"Efficacy and Safety of VVZ-149 Injections in Patients Undergoing Laparoscopic Colectomy","status":"COMPLETED","sponsor":"Vivozon Pharmaceutical Inc.","startDate":"2021-07-19","conditions":"Pain, Postoperative, Acute Pain","enrollment":285},{"nctId":"NCT03997838","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2019-05-23","conditions":"Pain, Postoperative","enrollment":307},{"nctId":"NCT02992041","phase":"PHASE2","title":"Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectomy","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2016-12-27","conditions":"Post-Operative Pain","enrollment":69},{"nctId":"NCT02489526","phase":"PHASE2","title":"Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2015-09-28","conditions":"Post-Operative Pain","enrollment":60},{"nctId":"NCT03997812","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2019-05-23","conditions":"Pain, Postoperative","enrollment":60},{"nctId":"NCT04430088","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of VVZ-149 Injections for Postoperative Pain Following Bunionectomy","status":"UNKNOWN","sponsor":"Vivozon, Inc.","startDate":"2020-06-26","conditions":"Pain, Postoperative","enrollment":300},{"nctId":"NCT04415645","phase":"PHASE1","title":"Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2020-02-24","conditions":"Healthy Adult Male","enrollment":6},{"nctId":"NCT01905410","phase":"PHASE1","title":"Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2013-07","conditions":"Healthy","enrollment":66},{"nctId":"NCT03347266","phase":"PHASE2","title":"Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2017-12-20","conditions":"Post-Operative Pain","enrollment":12},{"nctId":"NCT02333318","phase":"PHASE1","title":"A Single Ascending Dose Escalation to Investigate Safety and PK of VVZ-149 Injection in Healthy Older Male Volunteers","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2014-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT02844725","phase":"PHASE2","title":"Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2016-06","conditions":"Post-Operative Pain","enrollment":60},{"nctId":"NCT02522598","phase":"PHASE2","title":"Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy","status":"COMPLETED","sponsor":"Vivozon, Inc.","startDate":"2015-08","conditions":"Post-Operative Pain","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Opiranserin Injections","VVZ-149 injection or water for injection","Colorless, transparent liquid in water for injection","VVZ-149 injection"],"phase":"phase_3","status":"active","brandName":"VVZ-149 Injections","genericName":"VVZ-149 Injections","companyName":"Vivozon, Inc.","companyId":"vivozon-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VVZ-149 Injections is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}